高视医疗公告，全资附属公司高视泰靓医疗科技有限公司的"人工晶状体植入系统"获得广东省药品监督 管理局批准的医疗器械注册证。该系统适用于微小切口白内障手术中的人工晶状体植入手术，与2024年 获批的人工晶状体植入系统相比，将手术切口优化至1.8mm以内，能最大限度减少角膜创伤及加速术后 恢复。产品为高视泰靓原创设计，已获得发明专利授权。 ...

今年4月7日，受外部因素影响，高视医疗(02407)股价大幅下跌，单日跌幅达到15.99%。而后，公司股价开启缓慢爬升过程，5月7日，公司收盘价6.05港元， 已超过4月6日收盘价，宣告高视医疗正式修复此轮行情跌幅。 然而，拉长时间线来看，高视医疗整个4月份的股价跌幅依旧达到3.53%，相比之下恒生医疗保健板块的同期涨幅为1.10%。跑输板块的背后，或许与高视医 疗被踢出港股通以及2024年年报业绩表现不佳有关。 在大市震荡前被踢出港股通 回顾4月份，受外部环境因素负面影响，恒指4月7日在长假期后复市大跌13.2%，指数暴泻3021点，创下自亚洲金融危机以来最大单日跌幅，恒生医疗保健 指数当日也暴跌了19.01%，指数跌至2408.11点。 按照规则，被踢出港股通后，投资者只能继续持有或单向卖出。很显然，港股通资金并未在高视医疗上过多停留，截至5月7日，公司"出通"后股价累跌 25.22%。随着公司股价一路下滑，其港股通持股比例也降至5月7日的5.94%。 但仅过去10个交易日，恒生医疗保健指数便在盘中触及2978.74点，跃过4月6日收盘价成功"收复失地"，反弹表现明显较高视医疗更佳，究其原因在于南向 资金 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,428.4 million, an increase of 1.6% compared to RMB 1,406.2 million for the year ended December 31, 2023[11]. - The net profit for the year ended December 31, 2024, was RMB 88.5 million, a decrease of 48.8% from RMB 172.9 million in 2023[11]. - Basic earnings per share for the year ended December 31, 2024, were RMB 0.63, down from RMB 1.17 in 2023[11]. - The board proposed a final dividend of HKD 0.3 per share for the year ended December 31, 2024, compared to HKD 1.1 per share in 2023[11]. - The company's gross profit for the same period was RMB 663.4 million, which is a decrease of 4.1% year-over-year[21]. - Sales cost rose by 7.1% from RMB 714.6 million to RMB 765.0 million, slightly outpacing revenue growth due to rising material costs and procurement prices[41]. - Gross profit decreased by 4.1% from RMB 691.6 million to RMB 663.4 million, with gross margin dropping from 49.2% to 46.4%[42]. - Other income and gains fell by 41.3% from RMB 45.0 million to RMB 26.4 million, primarily due to foreign exchange losses[43]. - The company recorded a net profit of RMB 88.5 million for the year ending December 31, 2024, down from RMB 172.9 million for the previous year[51]. Product Development and Innovation - The company has successfully launched three domestically developed single-focus intraocular lenses and is currently developing high-end domestic intraocular lenses[13]. - A new generation of dry eye examination products has been registered and officially launched for sale[13]. - The company is advancing AI diagnostic screening applications and smart manufacturing technologies in its product development[13]. - The company achieved MDR CE certification for its hydrophilic acrylic intraocular lens product line, marking a significant milestone[13]. - The company has established a "Global 4+2" R&D layout, with 265 R&D personnel, accounting for approximately 30% of total staff[28]. - R&D expenditure for the reporting period was RMB 78.4 million, representing 20.9% of proprietary product revenue, indicating a strong focus on innovation[28]. - The company aims to enhance its R&D capabilities, which accounted for 38.2% of the net proceeds allocation[119]. Market Expansion and Partnerships - The company has established exclusive distribution agreements with 16 out of 18 overseas brand partners, enhancing its product portfolio and market position[14]. - The company’s overseas business has expanded, participating in large-scale exhibitions with over 5,000 attendees and achieving MDR CE certification for its hydrophilic acrylic intraocular lens product line[33]. - The company’s products are now sold in 52 countries and regions, with its Roland products available in 33 countries[34]. - The company has established exclusive distribution agreements with 16 overseas brand partners, including a new partnership with South Korea's Sometech Inc. for 3D 4K digital ophthalmic surgical microscopes[31]. - The company aims to enhance its product offerings and expand its market presence in Asia and Europe, while optimizing management processes for improved efficiency[19]. Financial Position and Cash Management - As of December 31, 2024, the group's cash and cash equivalents amounted to RMB 421.4 million, a decrease of 31.9% from RMB 618.7 million as of December 31, 2023, primarily due to dividend payments of RMB 148.5 million and loan repayments of approximately RMB 109.7 million during the reporting period[64]. - The group's debt-to-asset ratio as of December 31, 2024, was 34.8%, down from 39.1% as of December 31, 2023[68]. - The group continues to maintain a strong cash flow and financial resources to support its operational and expansion plans[64]. - The group has implemented internal control measures to enhance cash management and reduce financial risks[64]. - The fair value financial assets decreased from RMB 175.6 million as of December 31, 2023, to RMB 97.7 million as of December 31, 2024, reflecting the company's focus on enhancing cash management efficiency and seeking high-return investment opportunities[52]. Employee and Management Structure - The total employee cost for the group for the year ended December 31, 2024, was RMB 375.2 million, compared to RMB 352.5 million for the year ended December 31, 2023, reflecting an increase of approximately 6.1%[140]. - The group had a total of 884 employees as of December 31, 2024, up from 869 employees as of December 31, 2023[140]. - The company emphasizes talent development and cultural construction as part of its strategic initiatives[80]. - The leadership team is well-educated, with degrees from prestigious institutions such as the University of Wisconsin-Madison and Peking University[81][88]. - The company has a strong focus on compliance and internal audit functions, overseen by Zhao Xinli as Chief Compliance Officer[79]. Governance and Compliance - The board consists of five executive directors, one non-executive director, and three independent non-executive directors, maintaining compliance with listing rules[194]. - The independent non-executive directors play a crucial role in providing unbiased opinions on the company's strategy and performance[197]. - The company has adopted a corporate governance code to ensure compliance and protect shareholder interests[187]. - The board has established three committees: audit, remuneration, and nomination, to oversee specific aspects of governance[193]. - The board confirmed the independence of all independent non-executive directors throughout the reporting period[133]. Shareholder Information - Major shareholders include GT HoldCo with 63,263,528 shares, representing 42.78% of the total issued share capital[161]. - OrbiMed Advisors III Limited and its affiliates collectively hold 18,039,426 shares, accounting for 12.20% of the total issued share capital[161]. - The company has maintained a minimum of 25% public shareholding throughout the reporting period[177]. - The company has sufficient financial resources to implement share repurchases while maintaining a sound financial position[165]. - The company repurchased a total of 82,500 shares during the reporting period, at a total cost of HKD 976,492, representing 0.056% of the total issued shares[165].

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,428.4 million, an increase of 1.6% compared to RMB 1,406.2 million for the year ended December 31, 2023[2]. - The net profit for the year ended December 31, 2024, was RMB 88.5 million, a decrease of 48.8% from RMB 172.9 million recorded in 2023[2]. - Basic earnings per share for the year ended December 31, 2024, were RMB 0.63, down from RMB 1.17 in 2023[2]. - The gross profit for the year ended December 31, 2024, was RMB 663.4 million, a decrease of 4.1% from RMB 691.6 million in the previous year[6]. - The group achieved MDR CE certification for its hydrophilic acrylic intraocular lens product line, which is expected to lower costs and ensure long-term material supply[17]. - Total comprehensive income for the year was RMB 51,933,000, significantly lower than RMB 208,753,000 in 2023, a decline of approximately 75.1%[73]. - The company's total assets less current liabilities increased to RMB 2,054,497,000 in 2024 from RMB 1,952,050,000 in 2023, an increase of about 5.3%[75]. - Non-current liabilities rose to RMB 466,310,000 in 2024, compared to RMB 255,064,000 in 2023, reflecting an increase of approximately 83.0%[75]. - The group's total tax expense for the year 2024 is RMB 66,764,000, a decrease of 10.4% from RMB 74,821,000 in 2023[112]. - The effective tax rate for the group in 2024 is calculated at 43.0% based on the pre-tax profit of RMB 155,287,000, compared to 23.1% in 2023[113]. Revenue Breakdown - Revenue from the sale of ophthalmic medical consumables reached RMB 530.3 million, and revenue from technical services was RMB 226.5 million, both achieving historical highs[5]. - The company's proprietary products contributed RMB 375.8 million in revenue, a decrease of 1.6% from RMB 381.9 million in 2023[9]. - Technical services revenue increased by 8.3% to RMB 226.5 million, supported by a team of 133 engineers providing 24/7 service across Greater China[11]. - The self-owned products segment generated external sales of RMB 375,814,000, while the distribution products segment achieved RMB 819,321,000 in external sales[93]. - The technology services segment reported external sales of RMB 226,458,000, contributing to the overall revenue[93]. - Revenue from ophthalmic medical devices was RMB 664,878 thousand, down from RMB 680,271 thousand in 2023, representing a decrease of 2.0%[99]. - Revenue from ophthalmic medical consumables increased to RMB 530,257 thousand, up 3.9% from RMB 510,496 thousand in 2023[99]. Research and Development - The company has expanded its research and development capabilities with a "global 4+2" layout, including multiple platforms in China and two in Europe[4]. - R&D expenditure for the reporting period was RMB 78.4 million, representing 20.9% of self-owned product revenue, driven by increased investment in R&D projects to enhance independent innovation capabilities[12]. - Research and development expenses increased to RMB 78,418,000 in 2024 from RMB 52,883,000 in 2023, representing a rise of approximately 48.5%[71]. - The company plans to continue its focus on research and development in ophthalmic medical devices and consumables, aiming for market expansion in China and other regions[76]. - The group has a "global 4+2" R&D layout with 265 R&D personnel, accounting for approximately 30.0% of total employees, and an average of over ten years of industry experience[12]. Corporate Governance - The company has established an audit committee consisting of two independent non-executive directors and one non-executive director to oversee financial reporting and risk management[68]. - The company has committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[62]. - The company will continue to review and monitor its corporate governance practices to ensure compliance with applicable codes[65]. - The roles of Chairman and CEO were separated on March 25, 2024, with the appointment of a new CEO, Liu Xinwei[64]. - The company has a strong governance structure, including an audit committee and a board of directors to oversee its operations[140]. Market Expansion and Strategy - The group has established exclusive distribution agreements with 16 overseas brand partners, including a new partnership with South Korea's Sometech Inc. for 3D 4K digital ophthalmic surgical microscopes[15]. - The group’s products are sold in 52 countries and regions, with a focus on expanding market presence and product registration in new countries[17]. - The company is focused on developing and manufacturing its own products, particularly in the field of ophthalmology, including artificial lenses for cataract surgery[136]. - The company has a strategic plan to expand its market presence in the Greater China region, which includes mainland China, Hong Kong, Macau, and Taiwan[135]. - The company is actively engaging with key opinion leaders (KOLs) in the medical field to enhance its market influence and product adoption[136]. Financial Management - Cash and cash equivalents decreased by 31.9% from RMB 618.7 million as of December 31, 2023, to RMB 421.4 million as of December 31, 2024, primarily due to operational expenditures[43]. - The company has a total of RMB 507,728,000 in interest-bearing bank and other borrowings as of December 31, 2024, down from RMB 618,562,000 in 2023, a decrease of 18%[132]. - The company has secured a financing agreement for EUR 52.5 million to refinance existing loans, with a maturity date of December 22, 2027[133]. - The company maintains a diversified customer base for trade receivables, minimizing credit risk concentration[125]. - The company has implemented strict credit control measures to manage overdue receivables effectively[125]. Employee and Talent Management - As of December 31, 2024, the group had a total of 884 employees, an increase from 869 employees as of December 31, 2023[60]. - The total employee cost for the year ended December 31, 2024, was RMB 375.2 million, compared to RMB 352.5 million for the year ended December 31, 2023, reflecting an increase of approximately 6.1%[60]. - The company has adopted a share incentive plan to recognize and reward eligible participants for their contributions, aimed at attracting top talent[61]. - The company has implemented a training management system to enhance employee skills and support career development[60]. Dividend and Shareholder Returns - The company plans to propose a final dividend of HKD 0.3 per share for the year ended December 31, 2024, down from HKD 1.1 per share in 2023[2]. - The proposed final dividend per ordinary share for 2024 is HKD 0.30, significantly lower than HKD 1.10 in 2023, resulting in a total dividend payout of HKD 44,366,000 compared to HKD 162,767,000 in the previous year[112]. - The group paid a final dividend of RMB 148.5 million for the year ending December 31, 2023, and repaid loans totaling approximately RMB 109.7 million[44].

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million for the same period in 2023[23]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in the prior year[23]. - Basic earnings per share for the six months ended June 30, 2024, were RMB 0.19, compared to RMB 0.75 for the same period in 2023[23]. - Total revenue for the six months ended June 30, 2024, was RMB 529.1 million, a decrease of 10.8% from RMB 593.2 million for the same period in 2023[39]. - Gross profit decreased by 16.1% to RMB 298.4 million for the six months ended June 30, 2024, compared to RMB 355.6 million for the same period in 2023, with a gross margin decline from 50.8% to 46.5%[40]. - The technical services segment generated revenue of RMB 110.0 million, representing a year-on-year increase of 6.5%[29]. - Profit before tax decreased to RMB 58,395,000, a decline of 58.9% from RMB 142,229,000 in the previous year[100]. - Total comprehensive income for the period was RMB 7,110,000, down from RMB 147,170,000 in the same period last year[103]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in the previous year[23]. - The company has expanded its R&D capabilities with platforms in four cities in China and two in Europe, covering a global sales network across 51 countries[25]. - The company has established a "global 4+2" R&D layout with a total of 261 R&D personnel, representing approximately 29.9% of total employees[30]. - Research and development expenses rose by 34.5% to RMB 35.1 million, reflecting ongoing investments in product development and team expansion[47]. - Research and development expenses increased to RMB 35,140,000, up 34.6% from RMB 26,105,000 in the previous year[123]. Product and Market Development - The company has a product portfolio of 150 items, including 65 proprietary products, and has established exclusive distribution agreements with 16 overseas brand partners[25][28]. - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[27]. - The company is focusing on the development of surgical treatment products, particularly surgical equipment and consumables[35]. - The company has expanded its distribution network, partnering with 18 overseas brands, including exclusive agreements with 16 partners[33]. - The company aims to enhance its operational efficiency and strengthen brand and talent development as part of its long-term strategy[35]. Financial Position and Cash Flow - Cash and cash equivalents decreased by 11.6% from RMB 618.7 million as of December 31, 2023, to RMB 546.8 million as of June 30, 2024, mainly due to repayment of domestic loans[61]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[65]. - Total liabilities decreased to RMB 1,251,830,000 from RMB 1,146,731,000 at the end of 2023, indicating a shift in financial structure[105]. - Operating cash flow for the six months ended June 30, 2024, was RMB (10,829) thousand, a significant decrease from RMB 111,187 thousand in the same period of 2023[109]. - The company reported a net cash outflow from financing activities of RMB (59,304) thousand in 2024, compared to RMB (70,433) thousand in 2023, indicating a decrease in outflow of about 16%[110]. Shareholder Information - The largest shareholder, GT HoldCo, holds 42.75% of the issued share capital, amounting to 63,263,528 shares[90]. - As of June 30, 2024, the company had a total of 147,970,369 issued ordinary shares[2]. - The board of directors did not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous year[77]. - The company has adopted a share incentive plan to recognize and reward contributions from eligible participants, with no rewards granted under this plan as of the interim report date[72]. Foreign Exchange and Risk Management - The company reported a foreign exchange loss of RMB 198 million due to fluctuations in the Euro exchange rate during the reporting period[67]. - The company has no foreign currency hedging policy in place and continues to monitor foreign exchange risks[67]. - The company has implemented a credit verification process for all traders engaging in credit transactions[68]. Employee and Management Information - The total employee cost for the reporting period was RMB 184 million, an increase from RMB 169.6 million for the same period last year[71]. - The company had a total of 872 employees as of June 30, 2024, compared to 869 employees as of December 31, 2023[71]. - Total remuneration for key management personnel reached RMB 4,263,000 for the six months ended June 30, 2024, up from RMB 3,632,000 in 2023, reflecting a growth of 17.4%[162]. Acquisitions and Investments - The company completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[174]. - The group’s investment in private equity funds amounted to RMB 178,696,000, with an expected return rate between 2.5% and 4.5% annually[143].

Financial Performance - For the six months ended June 30, 2024, the company recorded revenue of RMB 642.0 million, a decrease of 8.4% compared to RMB 700.7 million in the same period of 2023[2]. - The net profit for the same period was RMB 26.9 million, down 75.6% from RMB 110.4 million in 2023[2]. - Basic earnings per share were RMB 0.19, compared to RMB 0.75 in the same period of 2023[2]. - Gross profit fell from RMB 355.6 million for the six months ended June 30, 2023, to RMB 298.4 million for the same period in 2024, a decrease of 16.1%[17]. - The gross margin decreased from 50.8% to 46.5%, mainly due to increased raw material and labor costs, changes in product sales mix, and a significant price drop for artificial lenses starting May 2024[18]. - Total comprehensive income for the period was RMB 7,110 thousand, significantly lower than RMB 147,170 thousand in 2023[60]. - The company's total equity was RMB 1,555,941 thousand, down from RMB 1,696,986 thousand at the end of 2023[63]. Revenue Breakdown - Revenue contribution from proprietary products was RMB 178.0 million, accounting for 33.6% of total sales, an increase from 32.7% in the previous year[6]. - Revenue from distribution products was RMB 351.0 million, a decrease of 12.1% due to ongoing impacts from domestic medical service policies and macroeconomic conditions[7]. - Revenue from self-owned products was RMB 178,005,000, down from RMB 193,868,000, representing a decline of 8.9%[67]. - Revenue from distribution products was RMB 351,048,000, a decrease of 12.1% from RMB 399,365,000[67]. - Revenue from ophthalmic medical devices was RMB 273,009,000, down from RMB 337,863,000, a decrease of 19.3%[70]. - Revenue from technical services increased to RMB 110,047,000, up from RMB 103,325,000, marking a growth of 6.6%[70]. Research and Development - Research and development expenses increased by 34.5% to RMB 35.1 million, representing 5.5% of revenue, up from 3.7% in 2023[2]. - The company's R&D expenditure reached RMB 35.1 million, a year-on-year increase of 34.5%, accounting for 19.7% of self-owned product revenue[9]. - The company has accelerated the development of domestic artificial lenses, obtaining medical device registration certificates ahead of schedule[4]. - The company has established a global R&D layout of "4+2" with 261 R&D personnel, representing approximately 29.9% of total employees[9]. - The company is investing €5 million in R&D for the development of advanced ophthalmic devices[99]. Expenses and Costs - Sales and distribution expenses slightly decreased by 4.5% to RMB 115.5 million, while the percentage of these expenses to revenue increased from 17.3% to 18.0%[21]. - Administrative expenses increased by 17.8% to RMB 73.6 million, mainly due to staff expansion in administrative departments[22]. - Financing costs decreased by 13.1% to RMB 20.6 million, attributed to the repayment of domestic loans and lower interest rates on new loans[23]. - Other expenses rose significantly from RMB 1.9 million to RMB 12.0 million, mainly due to increased inventory impairment provisions and foreign exchange losses[25]. Inventory and Assets - Inventory increased by 11.6% to RMB 366.7 million, leading to an increase in inventory turnover days from 159 to 187 days[29]. - Non-current assets totaled RMB 1,421,150 thousand as of June 30, 2024, compared to RMB 1,452,881 thousand at the end of 2023[61]. - Current assets amounted to RMB 1,386,621 thousand, slightly down from RMB 1,390,836 thousand at the end of 2023[61]. - Trade receivables, net of impairment, amounted to RMB 143,783,000 as of June 30, 2024, compared to RMB 146,543,000 as of December 31, 2023[87]. Liabilities and Financing - The group's interest-bearing bank and other borrowings amounted to RMB 568.2 million as of June 30, 2024, including short-term borrowings of RMB 216.2 million and long-term borrowings of RMB 352.0 million[38]. - The debt-to-asset ratio increased from 39.1% as of December 31, 2023, to 40.2% as of June 30, 2024[40]. - The company plans to utilize a financing agreement of EUR 52.5 million to refinance existing loans, with a maturity date set for December 22, 2027[92]. Market and Strategic Initiatives - The company plans to enhance its product offerings in surgical treatment, focusing on surgical equipment and consumables[13]. - The company aims to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[13]. - Market expansion efforts are focused on the Greater China region, with a target of increasing market share by 10%[97]. - The company has completed the acquisition of Teleon Holding B.V. for €24.25 million, enhancing its product portfolio[98]. - The company plans to enhance its distribution network in Europe, aiming for a 15% increase in sales through new partnerships[99]. Shareholder Returns and Dividends - The board does not recommend an interim dividend for the six months ended June 30, 2024, consistent with the previous period[49]. - The company announced a proposed final dividend of HKD 1.10 per share for the year ended December 31, 2023[82]. Audit and Compliance - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with financial reporting and risk management[54]. - The interim condensed consolidated financial statements for the six months ended June 30, 2024, were reviewed by the external auditor, Ernst & Young[56].

ai1713787694134_Gaush AR2023 Cover V15_24.5mm OP.pdf 1 22/4/2024 下午8:08 年報 2023 ANNUAL REPORT 2023 (Incorporated in the Cayman Islands with limited liability) Stock Code : 2407 年報 2023 ANNUAL REPORT 科技締造 光明視界 高視GAUSH (於開曼群島註冊成立的有限責任公司) 股份代號 : 2407 科技締造 光明視界 | --- | --- | --- | |-------|--------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目錄 | | | | 公司概況 | 2 | | | 公司資料 | 3 | | | | | | | 財務摘要 | 5 | | | 主席報告 | 6 | | | | | | | 管理層討論及分析 | 8 | | | 董事及高級管理 ...

Financial Performance - For the year ended December 31, 2023, the company's revenue was RMB 1,406.2 million, an increase of 12.2% compared to RMB 1,253.8 million for the year ended December 31, 2022[2]. - The net profit for the year ended December 31, 2023, was RMB 172.9 million, a significant recovery from a net loss of RMB 352.7 million in the previous year[2]. - The basic earnings per share for the year ended December 31, 2023, was RMB 1.17, compared to a basic loss per share of RMB 3.61 for the year ended December 31, 2022[2]. - The gross profit for the year ended December 31, 2023, was RMB 691.6 million, reflecting a 10.6% increase from RMB 625.3 million in the previous year[4]. - The company's revenue increased by 12.2% from RMB 1,253.8 million in 2022 to RMB 1,406.2 million in 2023, driven by higher sales of ophthalmic medical consumables and equipment[18]. - Sales of distributed products reached RMB 808.9 million in 2023, up from RMB 744.8 million in 2022, while proprietary products sales increased from RMB 308.3 million to RMB 381.9 million[19]. - Gross profit increased by 10.6% from RMB 625.3 million in 2022 to RMB 691.6 million in 2023, with a slight decrease in gross margin from 49.9% to 49.2%[21]. - The total comprehensive income for the year was RMB 208,753 thousand, compared to a loss of RMB 328,210 thousand in 2022[63]. Revenue Breakdown - Revenue from proprietary products reached RMB 381.9 million, accounting for 32.1% of total sales, up from 29.3% in the previous year[7]. - Revenue from distribution products was RMB 808.9 million, an increase of 8.6% from RMB 744.8 million in the previous year[8]. - The technical services segment generated revenue of RMB 209,234 thousand, up from RMB 190,084 thousand in 2022, showing a growth of approximately 10.6%[84]. - Revenue from the Greater China region was RMB 1,122,722 thousand, up from RMB 1,001,358 thousand in 2022, reflecting a growth of about 12.1%[81]. Research and Development - The R&D team has 240 personnel, accounting for approximately 28% of total employees, with R&D expenditure of RMB 52.9 million, representing 13.9% of proprietary product revenue, an increase of 28.7% from RMB 41.1 million in 2022[10]. - The company aims to increase R&D investment and enhance cooperation with upstream partners to achieve over 50% revenue contribution from proprietary products[17]. - The company’s R&D efforts include the development of an automatic fundus camera and optical biometer, with the automatic fundus camera showing increasing market demand[11]. - Research and development expenses amounted to RMB 52,883,000, up from RMB 41,089,000 in the previous year, marking a growth of 28.7%[92]. Expenses and Costs - The cost of sales rose by 13.7% from RMB 628.4 million in 2022 to RMB 714.6 million in 2023, primarily due to increased raw material costs for proprietary products and higher procurement prices for imported products[20]. - Sales and distribution expenses surged by 32.5% from RMB 187.8 million in 2022 to RMB 248.8 million in 2023, attributed to the resumption of offline marketing activities post-pandemic[23]. - Administrative expenses decreased by 11.5% from RMB 146.2 million for the year ended December 31, 2022, to RMB 129.4 million for the year ended December 31, 2023, primarily due to the absence of listing expenses in 2023[24]. - Financing costs increased by 18.5% from RMB 42.7 million for the year ended December 31, 2022, to RMB 50.6 million for the year ended December 31, 2023, mainly due to rising interest rates on bank and other borrowings[25]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of HKD 1.1 per share for the year ended December 31, 2023, subject to shareholder approval[2]. - The company proposed a final dividend of HKD 1.10 per share for the year ending December 31, 2023, compared to no dividend in 2022, amounting to HKD 162,767,000[102]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adopted a corporate governance code[54]. - The chairman and CEO roles are held by the same individual, which the board believes does not affect the balance of power and authority[55]. - The company has established an audit committee to oversee financial reporting and risk management processes[58]. Market Expansion and Strategy - The company has expanded its distribution network, partnering with 19 overseas brands, including Haag-Streit, to enhance its product offerings and market reach[12]. - The company is expanding its market presence in the Greater China region, targeting a 25% increase in market share by 2025[125]. - The company plans to strengthen its market presence in Asia and Europe while balancing domestic and international business growth[17]. Assets and Liabilities - Non-current assets increased to RMB 1,452,881 thousand as of December 31, 2023, from RMB 1,391,756 thousand in 2022[64]. - The company's total equity increased to RMB 1,696,986 thousand as of December 31, 2023, compared to RMB 1,486,685 thousand in 2022[66]. - The total amount of borrowings as of December 31, 2023, was RMB 618,562,000, compared to RMB 701,588,000 in 2022, showing a decrease of 11.8%[118]. Future Outlook - The company has provided a revenue guidance of $85 million for the fiscal year 2024, which reflects a projected growth of approximately 13%[125]. - New product launches are expected to contribute an additional $10 million in revenue in 2024, focusing on innovative medical devices[125]. - The board of directors remains optimistic about the long-term growth trajectory, citing strong fundamentals and a robust pipeline of new products[125].

Financial Performance - The company reported revenue of RMB 700.7 million for the six months ended June 30, 2023, representing a 21.2% increase from RMB 577.9 million in the same period of 2022[19]. - The net profit for the company was RMB 110.4 million, compared to a net loss of RMB 53.3 million in the same period of 2022, marking a significant turnaround[19]. - Basic earnings per share increased to RMB 0.75, compared to a basic loss per share of RMB 0.54 in the same period of 2022[19]. - The gross profit for the six months ended June 30, 2023, was RMB 355.6 million, reflecting a 26.5% increase from the previous year[20]. - The company's other income and gains rose from RMB 13.9 million to RMB 21.8 million, mainly due to foreign exchange gains of RMB 7.3 million in the first half of 2023 compared to a loss of RMB 84.6 million in the same period of 2022[36]. - The company reported a total comprehensive income of RMB 147,170 thousand for the period, compared to a loss of RMB 65,286 thousand in the same period last year[85]. - The company reported a net cash flow from operating activities of RMB 111,187,000 for the six months ended June 30, 2023, compared to RMB 75,268,000 for the same period in 2022, representing a year-over-year increase of about 47.8%[92]. - The company reported a pre-tax profit of RMB 142,229,000 for the six months ended June 30, 2023, compared to a loss of RMB 32,147,000 in the same period of 2022[114]. Research and Development - Research and development expenses were RMB 26.1 million, up 16.5% from RMB 22.4 million in the same period of 2022, maintaining a stable ratio of approximately 3.7% of revenue[19]. - The company has established a "global 4+2" R&D layout with seven R&D and production platforms in China and two overseas in the Netherlands and Germany[20]. - The company continues to invest in R&D and has appointed Dr. Alexey Nikolaevich Simonov as the Chief Technology Officer[20]. - R&D expenditure was RMB 26.1 million, accounting for 3.7% of total revenue, a 16.5% increase from RMB 22.4 million in the same period last year[26]. - The company aims to enhance its proprietary product revenue share and increase investment in surgical treatment products while maintaining its leading position in diagnostic products[29]. - The company is advancing the registration of the new generation ATOS femtosecond corneal refractive surgery system and the ANTERION multimodal imaging platform[28]. - The company has invested 10 million euros in R&D for the development of innovative glaucoma treatments[151]. Sales and Market Presence - Sales of proprietary products reached RMB 193.9 million, accounting for 32.7% of total product sales, setting a new record[20]. - Revenue from proprietary products reached RMB 193.9 million, accounting for 32.7% of total sales, a 36.5% increase from RMB 142.0 million in the same period last year[23]. - Revenue from distribution products was RMB 399.4 million, representing 67.3% of total sales, up 17.9% from RMB 338.7 million year-over-year[24]. - The company serves over 4,000 end customers in China, including more than 1,200 tertiary hospitals and 1,500 secondary hospitals[20]. - The company has partnered with 19 overseas brand partners, with 17 having exclusive distribution agreements, including two new partners added during the reporting period[20]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2024[151]. Expenses and Costs - Selling and distribution expenses increased by 34.2% to RMB 120.9 million, representing 17.3% of revenue, up from 15.6% in the previous year[37]. - Administrative expenses decreased by 10.5% to RMB 62.5 million, primarily due to the absence of listing expenses incurred in the previous year[38]. - Financing costs slightly increased from RMB 20.7 million to RMB 23.7 million, attributed to higher interest expenses on domestic loans and preferred financing loans[39]. - The cost of goods sold increased to RMB 345,096,000, up from RMB 296,633,000, representing a growth of approximately 16.3% year-over-year[106]. - Employee benefits expenses amounted to RMB 48,467,000 for the six months ended June 30, 2023, compared to RMB 44,297,000 for the same period in 2022, reflecting an increase of about 4.9%[107]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 1,969,859 thousand, an increase from RMB 2,225,467 thousand as of December 31, 2022[86]. - Current liabilities increased to RMB 878,342 thousand from RMB 492,623 thousand at the end of the previous year[86]. - Cash and cash equivalents decreased by 10.9% from RMB 721.5 million as of December 31, 2022, to RMB 642.5 million as of June 30, 2023, due to the use of operating surplus funds for investments in financial assets[55]. - Trade receivables decreased from RMB 166.4 million as of December 31, 2022, to RMB 158.9 million as of June 30, 2023, due to improved collection management[49]. - Trade payables increased from RMB 68.7 million as of December 31, 2022, to RMB 96.6 million as of June 30, 2023, primarily due to preemptive stockpiling after the lifting of pandemic control measures[50]. - The debt-to-asset ratio improved from 50.9% as of December 31, 2022, to 46.1% as of June 30, 2023[57]. Corporate Governance and Management - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable corporate governance codes[64]. - The company has adopted a code of conduct for securities trading, ensuring all directors complied with the standards during the reporting period[65]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[66]. - The company has no other disclosure obligations under the Listing Rules apart from what is disclosed in the interim report[79]. - The company has maintained a stable relationship with its related parties, with minimal transactions reported in the current period compared to the previous year[137]. Future Outlook - The company plans to focus on obtaining regulatory approvals for new products and expanding its market presence in the second half of 2023[30]. - The company aims to leverage its product line and brand advantages to ensure favorable bidding outcomes for its ophthalmic products[30]. - The company plans to increase its workforce by 15% to support its expansion and R&D efforts[151]. - A strategic acquisition of a technology firm is anticipated to enhance the company's R&D capabilities and product offerings[150].

[41 -> 70] 各位参议师以及投资者朋友们,大家上午好。欢迎各位出席高市医疗2023年度中期业绩发布会。首先,我们有请田圆女士做开场介绍。大家好,欢迎各位参会。首先介绍一下,参加本次发布会的公司管理层代表有高市医疗创始人、董事长兼首席执行官高铁塔先生、联席CEO兼执行董事刘新伟先生、 [70 -> 96] 以及首席财务官执行董事,尽涉及内在风险及不确定因素,可能导致实际业绩偏离当前的预期。有关该等风险及不确定因素的详细论述,请参阅高市医疗向香港交易所递交的最新公告内容。 [96 -> 126] 本次会议中所提供的一切紧张性陈述均基于我们认为截至今日合理的假设高市医疗并不承担更新该等陈述的任何义务除非适用法律另有规定本次讨论还包含某些非国际财务报告准则的财务措施仅供比较之用稍后刘兴伟先生将首先向大家介绍高市医疗的业务发展情况及未来展望第二部分由李文琪女士帮我们回顾公司的财务表现 [126 -> 156] 在管理层的讲解之后 在管理层的讲解之后 我们将会举行一个简单的问答环节 我们将会举行一个简单的问答环节 各位如需与管理层进行线上提问 各位如需与管理层进行线上提问 可通过举手语音提问或文字提问 可通过举手 ...